Ayvakit (avapritinib) — Highmark
Gastrointestinal Stromal Tumor (GIST)
Initial criteria
- age ≥ 18 years
- diagnosis of unresectable or metastatic GIST (ICD-10: C49.A)
- disease harbors a PDGFRA exon 18 mutation
Reauthorization criteria
- prescriber attests that the member is tolerating therapy
- therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months